BUSINESS
U.S. Food and Drug Administration Places Clinical Hold On Cellectis MELANI-01...
Cellectis a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced that the MELANI-01 trial has...
MEDICAL DEVICES
MANUFACTURING
Helix BioPharma Corp. announces the signing of a non-binding letter of...
Helix BioPharma Corp., a clinical stage immuno-oncology company developing drug candidates for the prevention and treatment of cancer, announced that it has signed a...
DON'T MISS
JOURNAL SPOTLIGHT
PharmaCyte Biotech’s Cannabinoid Therapy May Offer Potential for Childhood Brain Cancers
LAGUNA HILLS, Calif., Dec. 27, 2016 - PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and...
EVEN MORE NEWS
